The phase II study (NCT02484404) with olaparib plus the PD-L1 inhibitor (durvalumab), was performed for platinum-resistant recurrent ovarian cancer, and a response rate (RR) of 15% and stable disease (SD) of 38% yielded a disease control rate (DCR) of 53% [93]. This evidence concerns the gene CD274 and ovarian carcinoma.